Casey Chapman

Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial

1 Nancy University Hospital, Vandoeuvre-les-Nancy, France; 2 GI Alliance, United States; 3 Icahn School of Medicine at Mount Sinai, New York, United States; 4 UNIMI, Department of Pathoph...

Xiu Huang ;

Sofie Berg ;

Lei Shu ;

Kristina Kligys ;

Remo Panaccione ;

Marc Ferrante ;

Britta Siegmund ;

Jean-Frederic Colombel ;

Ezequiel Neimark ;

Geert D'Haens ;

Kori Wallace ;

Marla C. Dubinsky , MD;

Peter Irving ;

W. Rachel Duan ;

Flavio Caprioli ;

Stefan Schreiber ;

Laurent Peyrin-Biroulet ;

Raja Atreya ;

Silvio Danese ;

James O. Lindsay ;

Casey Chapman ;

Peter Bossuyt ;

Toni Anschutz ;

Valerie Pivorunas ;

01/11/2024

Biologic Therapy Sequencing in Ulcerative Colitis: A Real-World Observational Study of Second-Line Therapy After Vedolizumab

1 Anne Marion Burnett School of Medicine, Fort Worth, Texas, United States; 2 Healix Infusion Therapy, LLC, Sugar Land, Texas, United States; 3 GI Alliance, United States; 4 Takeda Pharma...

Casey Chapman ;

Lisa Young ;

Timothy Ritter ;

Lucinda J. Van Anglen ;

Christopher Fernandes ;

Precious A. Anyanwu ;

Harry Sarles ;

Chiahung Chou ;

Jeanne Jiang ;

Marie Sanchirico ;

Tao Fan ;

01/11/2024

P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice

BACKGROUND: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that is a life-long condition with a relapsing and remitting course. As with other chronic diseases,...

Hartman Brunt ;

Diana Hamer ;

Casey Chapman ;

12/15/2021